← Back to Search

Brachytherapy

HDR Brachytherapy for Prostate Cancer

Q: How many individuals have signed up for participation in this clinical trial thus far?

<p>Indeed, the current information on clinicaltrials.gov points to this trial being actively recruiting patients. This study was initially published in October 2016 and last modified in 2020 - with a goal of 30 participants at 1 site.</p>

Q: Are there any vacancies still available for individuals to take part in this research?

<p>According to clinicaltrials.gov, this research project is actively recruiting participants as of October 20th 2022 - after it was initially opened for enrollment on 14th October 2016.</p>

N/A

Recruiting

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No TRUP within the past 6 months, nor large TURP defect

Age ≥ 18 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 yrs

Awards & highlights

Study Summary

This trial will investigate a new, more targeted form of radiation therapy for prostate cancer, which may result in fewer side effects and improved quality of life.

Who is the study for?

Men over 18 with early-stage, low to favorable intermediate-risk prostate cancer can join this study. They should be in good health (ECOG status 0-2), have a prostate size <80cc, and no history of severe rectal conditions or certain autoimmune diseases. No prior radiation or brachytherapy for the prostate is allowed, and they must not have any contraindications to MRI or anesthesia.Check my eligibility

What is being tested?

The trial is testing two types of high dose rate (HDR) brachytherapy treatments for localized prostate cancer: one that targets the whole gland and another that focuses on specific areas identified by MRI. The goal is to see if focal treatment reduces side effects while maintaining effectiveness.See study design

What are the potential side effects?

Potential side effects include urinary discomfort, incontinence, rectal symptoms like bleeding or pain, and sexual dysfunction such as erectile problems. These are common with traditional whole-gland treatments; the trial will assess if focal therapy lessens these issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I haven't had a prostate surgery or a large prostate tissue removal in the last 6 months.

Select...

I am 18 years old or older.

Select...

I am able to care for myself and perform daily activities.

Select...

My prostate cancer is confirmed by tissue analysis.

Select...

My prostate is smaller than 80cc.

Select...

I can safely undergo general or spinal/epidural anesthesia.

Select...

I don't have bleeding disorders and can stop blood thinners for brachytherapy.

Select...

I have never had Ulcerative Colitis, Crohn's Disease, Ataxia Telangiectasia, or Lupus.

Select...

I don't have severe hemorrhoids, recent colorectal surgery, or a missing rectum.

Select...

I have not had radiation therapy to my pelvis or prostate.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 yrs

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 yrs

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 yrs for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

number of patients achieving biochemical control

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Tumour visible on MRIExperimental Treatment1 Intervention

Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose

Group II: No tumour visible on MRIActive Control1 Intervention

Whole-gland HDR Brachytherapy

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,474 Previous Clinical Trials

485,012 Total Patients Enrolled

63 Trials studying Prostate Cancer

15,370 Patients Enrolled for Prostate Cancer

Media Library

Targeted Focal HDR Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT02918253 — N/A

Prostate Cancer Research Study Groups: No tumour visible on MRI, Tumour visible on MRI

Prostate Cancer Clinical Trial 2023: Targeted Focal HDR Brachytherapy Highlights & Side Effects. Trial Name: NCT02918253 — N/A

Targeted Focal HDR Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02918253 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have signed up for participation in this clinical trial thus far?

"Indeed, the current information on clinicaltrials.gov points to this trial being actively recruiting patients. This study was initially published in October 2016 and last modified in 2020 - with a goal of 30 participants at 1 site."

Answered by AI

Are there any vacancies still available for individuals to take part in this research?

"According to clinicaltrials.gov, this research project is actively recruiting participants as of October 20th 2022 - after it was initially opened for enrollment on 14th October 2016."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

HDR Focal: Feasibility Study

2016. "HDR Focal: Feasibility Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02918253.

All > Canada Prostate Cancer